Journal of Medicinal Chemistry · 2005 · 237 citations · 10 references
Life SciencesOncologyPharmacologyApoptosisCancer PharmacologyDrug DiscoveryApoptosis In CancerApoptosis PharmacologyApoptosis RegulationApoptotic SignalingExtrinsic Apoptotic PathwayAnti-apoptotic AgentsAnticancer ActivityAnticancer ChemotherapyApoptotic Signaling In CancerCancer Cell ApoptosisCompound IdentificationDrug-induced ApoptosisHigh-throughput Cell Screening
We have identified 5-(3-chlorothiophen-2-yl)-3-(4-trifluoromethylphenyl)-1,2,4-oxadiazole (1d) as a novel apoptosis inducer through our caspase- and cell-based high-throughput screening assay. Compound 1d has good activity against several breast and colorectal cancer cell lines but is inactive against several other cancer cell lines. In a flow cytometry assay, treatment of T47D cells with 1d resulted in arrest of cells in the G(1) phase, followed by induction of apoptosis. SAR studies of 1d showed that the 3-phenyl group can be replaced by a pyridyl group, and a substituted five-member ring in the 5-position is important for activity. 5-(3-Chlorothiophen-2-yl)-3-(5-chloropyridin-2-yl)-1,2,4-oxadiazole (4l) has been found to have in vivo activity in a MX-1 tumor model. Using a photoaffinity agent, the molecular target has been identified as TIP47, an IGF II receptor binding protein. Therefore, our cell-based chemical genetics approach for the discovery of apoptosis inducers can identify potential anticancer agents as well as their molecular targets.
10
Henriette Gourdeau, Lorraine Leblond, Bettina A. Hamelin et al. · Molecular Cancer Therapeutics · 2004 · 289 citations
William Kemnitzer, John Drewe, Songchun Jiang et al. · Journal of Medicinal Chemistry · 2004 · 279 citations